| Date Filed | Type | Description |
| 06/16/2023 |
4
| Windham-Bannister Susan Richards (Director) has filed a Form 4 on Humacyte, Inc.|
Txns:
| Granted 8,500 options to buy
@ $3.35, valued at
$28.5k
|
|
| 06/15/2023 |
4
| Windham-Bannister Susan Richards (Director) has filed a Form 4 on Aridis Pharmaceuticals, Inc.|
Txns:
| Granted 15,000 options
@ $0.16, valued at
$2.4k
Exercised 5,000 restricted stock units
@ $0 |
|
| 12/07/2022 |
4
| Windham-Bannister Susan Richards (Director) has filed a Form 4 on Aridis Pharmaceuticals, Inc.|
Txns:
| Granted 10,000 restricted stock units
@ $0 |
|
| 06/13/2022 |
4
| Windham-Bannister Susan Richards (Director) has filed a Form 4 on Humacyte, Inc.|
Txns:
| Granted 8,500 options to buy
@ $4.34, valued at
$36.9k
|
|
| 06/03/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/15/2021 |
4
| Windham-Bannister Susan Richards (Director) has filed a Form 4 on Humacyte, Inc.|
Txns:
| Granted 13,000 options to buy
@ $10.03, valued at
$130.4k
|
|
| 10/05/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/27/2021 |
3
| Windham-Bannister Susan Richards (Director) has filed a Form 3 on Humacyte, Inc. |
| 03/12/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/12/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 08/29/2019 |
4/A
| Windham-Bannister Susan Richards (Director) has filed a Form 4 on Aridis Pharmaceuticals, Inc.|
Txns:
| Granted 35,000 options
@ $10.01, valued at
$350.4k
|
|
| 07/15/2019 |
4
| Windham-Bannister Susan Richards (Director) has filed a Form 4 on Aridis Pharmaceuticals, Inc.|
Txns:
| Granted 35,000 options
@ $10.01, valued at
$350.4k
|
|
| 06/17/2019 |
3
| Windham-Bannister Susan Richards (Director) has filed a Form 3 on Aridis Pharmaceuticals, Inc. |
| 06/21/2018 |
4
| Windham-Bannister Susan Richards (Director) has filed a Form 4 on CAMBRIDGE BANCORP|
Txns:
| Granted 347 shares
@ $0 |
|
| 10/17/2017 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |